Increasing external beam dose for T1-T2 prostate cancer: Effect on risk groups Journal Article


Authors: Thames, H. D.; Kuban, D. A.; DeSilvio, M. L.; Levy, L. B.; Horwitz, E. M.; Kupelian, P. A.; Martinez, A. A.; Michalski, J. M.; Pisansky, T. M.; Sandler, H. M.; Shipley, W. U.; Zelefsky, M. J.; Zietman, A. L.
Article Title: Increasing external beam dose for T1-T2 prostate cancer: Effect on risk groups
Abstract: Purpose: The aim of this study was to investigate effect of increasing dose on risk groups for clinical failure (CF: local failure or distant failure or hormone ablation or PSA ≥25 ng/ml) in patients with T1-T2 prostate cancer treated with external beam radiotherapy. Methods and Materials: Patients (n = 4,537) were partitioned into nonoverlapping dose ranges, each narrow enough that dose was not a predictor of CF, and risk groups for CF were determined using recursive partitioning analysis (RPA). The same technique was applied to the highest of these dose ranges (70-76 Gy, 1,136 patients) to compare risk groups for CF in this dose range with the conventional risk-group classification. Results: Cutpoints defining low-risk groups in each dose range shifted to higher initial PSA levels and Gleason scores with increasing dose. Risk groups for CF in the dose range 70-76 Gy were not consistent with conventional risk groups. Conclusions: The conventional classification of risk groups was derived in the early PSA era, when total doses <70 Gy were common, and it is inconsistent with risk groups for patients treated to doses >70 Gy. Risk-group classifications must be continuously re-examined whenever the trend is toward increasing total dose. © 2006 Elsevier Inc. All rights reserved.
Keywords: controlled study; treatment failure; major clinical study; cancer radiotherapy; radiation dose; prostate specific antigen; radiotherapy dosage; radiotherapy; patient monitoring; prediction; risk; prostate cancer; gleason score; prostate-specific antigen; prostatic neoplasms; external beam radiotherapy; high risk population; hormones; dosimeters; ablation; risk groups; clinical disease-free survival; multi-institutional analysis; recursive functions
Journal Title: International Journal of Radiation Oncology, Biology, Physics
Volume: 65
Issue: 4
ISSN: 0360-3016
Publisher: Elsevier Inc.  
Date Published: 2006-07-15
Start Page: 975
End Page: 981
Language: English
DOI: 10.1016/j.ijrobp.2006.02.043
PUBMED: 16750319
PROVIDER: scopus
DOI/URL:
Notes: --- - "Cited By (since 1996): 16" - "Export Date: 4 June 2012" - "CODEN: IOBPD" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Michael J Zelefsky
    754 Zelefsky